BioCentury | Apr 14, 2014
Financial News

EpiTherapeutics financial update

...the total raised in the round to €15.7 million ($21.2 million). Existing investors Novo Seeds; Seed Capital Denmark...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

...preclinical small molecules against epigenetic targets for cancer $6.5M series A (Feb 2013) Novo Seeds; Seed Capital Denmark...
BioCentury | Apr 1, 2013
Financial News

EpiTherapeutics completes venture financing

...Cancer Date completed: 2/27/13 Type: Venture financing Raised: €5 million ($6.5 million) Investors: Novo Seeds; Seed Capital Denmark...
BioCentury | Dec 24, 2012
Emerging Company Profile

Aros: Easing IBS pain

...COO Gert Bolwig said. Aros was formed in 2009 by investors at Novo Seeds and SEED Capital Denmark...
...partners: Not disclosed Number of employees: Not disclosed Funds raised: Not disclosed Investors: Novo Seeds, SEED Capital Denmark...
Items per page:
1 - 4 of 4
BioCentury | Apr 14, 2014
Financial News

EpiTherapeutics financial update

...the total raised in the round to €15.7 million ($21.2 million). Existing investors Novo Seeds; Seed Capital Denmark...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

...preclinical small molecules against epigenetic targets for cancer $6.5M series A (Feb 2013) Novo Seeds; Seed Capital Denmark...
BioCentury | Apr 1, 2013
Financial News

EpiTherapeutics completes venture financing

...Cancer Date completed: 2/27/13 Type: Venture financing Raised: €5 million ($6.5 million) Investors: Novo Seeds; Seed Capital Denmark...
BioCentury | Dec 24, 2012
Emerging Company Profile

Aros: Easing IBS pain

...COO Gert Bolwig said. Aros was formed in 2009 by investors at Novo Seeds and SEED Capital Denmark...
...partners: Not disclosed Number of employees: Not disclosed Funds raised: Not disclosed Investors: Novo Seeds, SEED Capital Denmark...
Items per page:
1 - 4 of 4